While the use of this drug in PD is warranted by several reports showing its safety and antipsychotic efficacy in PD, [42–44] this drug is poorly effective in blocking D3 dopamine receptors, [45,46] which are considered to play a key role in DRT-associated ICDs. This evidence concerns the gene DRD3 and Parkinson disease.